Looking to publish in Liver Cancer? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Try Livewrite NowLiver Cancer publishes clinical and translational research on the causes, mechanisms, prevention, surveillance, diagnosis, and treatment of liver malignancy in humans and experimental models, including molecular targeted therapy, in the form of original and review articles.
Looking to publish in Liver Cancer? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Try Livewrite NowSubmission Instructions
Liver Cancer accepts the following article types. Click on an article type to view submission instructions.
Research Article
Review Article
Systematic Review
Case Report
Guidelines
Letter
Registered Report-Stage 1
Registered Report-Stage 2
Recent Publications
Real-World Evidence from a Nationwide Prospective Study of the Efficacy/Safety of Systemic Therapy for Unresectable Hepatocellular Carcinoma: First 1,000 Patients of the PRISM Study
Masafumi Ikeda, Shinji Itoh, Daisuke Onozuka, Sadahisa Ogasawara, Tomokazu Kawaoka, Takashi Niizeki, Taro Yamashita, Yasuhito Tanaka, Tomoharu Yamada, Kazushi Numata, Ryosuke Tateishi, Tatsuya Yamashita, Takuji Okusaka, Junji Furuse, Masatoshi Kudo
Methodological Concerns in “Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma”
Shoujun Shen, Jiayan Chen, Bihua Yao
Real-World Efficacy and Safety of TACE Combined with Lenvatinib and PD-1 Inhibitor in Conversion Therapy for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study
Lin Ye, Guo-Xing Liu, Da-Long Yang, Fan-Jian Zeng, Jie Liu, Hong-Bing Yao, Jun-Liang Nong, Shao-Ping Liu, Ning Peng, Wen-Feng Li, Pei-Sheng Wu, Chuang Qin, Ze Su, Jun-Jie Ou, Xiao-Feng Dong, Yi-He Yan, Teng-Meng Zhong, Ming-Song Wu, Yao-Zhi Chen, Guo-Dong Wang, Mian-Jing Li, Xue-Yao Wang, Fu-Quan Yang, Shu-Chang Chen, Yong-Yu Yang, Kang Chen, Yong-Cheng Lai, Qing-Qing Pang, Xiu-Mei Liang, Xian-Shuang Mao, Yong-Rong Liang, Fu-Xin Li, Hao Shi, Ren-Jian Li, Bang-De Xiang, Liang Ma, Jian-Hong Zhong, Ya-Qun Yu
Addition of Intra-arterial Therapy to Immunotherapy Improves Outcomes in Unresectable Hepatocellular Carcinoma: Taiwan Multicenter Cohort Study
Teng-Yu Lee, Pei-Chang Lee, Ying-Chun Shen, Wei-Fan Hsu, Shiue-Wei Lai, Ching-Wei Chang, Yung-Yeh Su, Tung-Hung Su, Po-Ting Lin, Chia-Yen Dai, Ching-Sheng Hsu, San-Chi Chen, Kun-Ming Rau, I-Cheng Lee, Song-Ru Jhan, Tsung-Hao Liu, Hsueh-Chou Lai, Tsang-En Wang, Shi-Ming Lin, Po-Cheng Liang, Cheng-Hao Tseng, Pi-Yi Chang, Shu-Cheng Wu, Hung-Wei Wang, Shou-Wu Lee, Yi-Hsiang Huang
Frequently asked questions
How long does it take to publish?
Accepted papers are published online in the unedited original manuscript version within a few days of acceptance. Authors should respond to proof queries within 48 hours. Articles are published electronically ahead of print shortly after author approval to publish.
Reformat to Liver Cancer using Livewrite PremiumIs a cover letter required?
A cover letter is required and should describe the gap in knowledge addressed by the manuscript, the implications and significance of the research, how the manuscript fits the journal scope, and the manuscript’s unique and important contributions. Submissions for a special issue or article collection should name the collection and identify who invited the submission where appropriate.
Reformat to Liver Cancer using Livewrite PremiumWhat are the publication costs?
Article Processing Charges (APCs) apply for Gold Open Access and Open Access options in hybrid journals; waivers and discounts are available for authors without means.
Reformat to Liver Cancer using Livewrite Premium